OTTAWA, ON, July 17, 2021 /CNW/ - Lemond Food Corp. is recalling HanSang brand Pork & Vegetable Gyoza from the marketplace because it contains milk and coconut which are not declared on the label. People with an allergy to milk or coconut should not consume the recalled product described below.
The following product has been sold in Ontario, Quebec, New Brunswick, Nova Scotia, and Prince Edward Island and may have been distributed in other provinces or territories.
Recalled product
Brand
Product
Size
UPC
Codes
HanSang
Gyoza ?
Pork & Vegetable
680 g
7 61898 71329 7
04.06.2023
What you should do
Check to see if you have the recalled product in your home. Recalled products should be thrown out or returned to the store where they were purchased.
If you have an allergy to milk or coconut, do not consume the recalled product as it may cause a serious or life-threatening reaction.
This recall was triggered by a recall in another country. The Canadian Food Inspection Agency (CFIA) is conducting a food safety investigation, which may lead to the recall of other products. If other high-risk products are recalled, the CFIA will notify the public through updated Food Recall Warnings.
The CFIA is verifying that industry is removing the recalled product from the marketplace.
Reactions
There have been no reported reactions associated with the consumption of this product.
Genexine (KOSDAQ: 095700), a publicly-listed, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of serious unmet medical needs, announced a merger with EPD Biotherapeutics...
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period.
The...
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...